Angiographic Complexity, Coronary Lesion, Males, Premature Ischemia, Testosterone
Conditions
Brief summary
This study aims to investigate the association between serum testosterone levels and the angiographic complexity of coronary artery lesions in male patients under 45 years of age presenting with premature ischemic heart disease.
Detailed description
Coronary artery disease (CAD) remains a leading cause of morbidity and mortality worldwide. While traditionally associated with older populations, there is a growing incidence of premature CAD. Testosterone, the primary male sex hormone, exerts various physiological effects beyond its role in reproductive function. It influences muscle mass, fat distribution, insulin sensitivity, and vascular tone. Low testosterone levels have been associated with adverse metabolic profiles, including increased adiposity, dyslipidemia, and insulin resistance, all of which are established risk factors for atherosclerosis. Furthermore, testosterone deficiency has been linked to endothelial dysfunction, a critical early event in the development of atherosclerotic plaques.
Interventions
OTHERCoronary Angiography
All angiographic procedures will be performed. Coronary artery disease will be defined as \>70% stenosis in at least one major epicardial artery or \>50% the left main coronary artery.
OTHERSyntax Score
The angiographic complexity of coronary artery disease (CAD) will be assessed using the SYNTAX score.
Sponsors
Sohag University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
No minimum to 45 Years
Healthy volunteers
No
Inclusion criteria
* Male patients aged \<45 years. * Diagnosed with premature ischemic heart disease. * Undergoing elective coronary angiography for suspected coronary artery disease (CAD) .
Exclusion criteria
* History of acute coronary syndrome within the preceding 3 months. * Prior diagnosis of hypogonadism or history of testosterone replacement therapy or anabolic steroid use. * Active neoplasm or history of chemotherapy. * Known hepatic cirrhosis, chronic kidney disease, or end-stage renal disease. * Use of medications known to affect sex hormone levels (e.g., spironolactone, ketoconazole). * Endocrine disorders such as sickle cell anemia or celiac disease.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum testosterone level | Immediately after angiography (Up to 1 hour) | Serum testosterone level will be measured. |
Countries
Egypt
Contacts
Primary ContactRemon S Adly, MD
Outcome results
None listed